August 7, 2019 – This webinar will explain how real-world evidence and innovative contracting can accelerate approval of drugs for rare diseases and facilitate reimbursement by payers so patients get their drugs quicker.
A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.
Certara Scientists to Highlight Model-informed Drug Development, PBPK, MBMA and QSP Progress at PAGE 2019
Certara is contributing to 28 sessions, showcasing modeling by its pharmacometricians, systems pharmacologists, and experts in pharmacoeconomics/health economics outcomes research
Advanced Analytics Using RWD Can Mitigate Risks in AD Drug Development, Reimbursement and Utilization
This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease drug approval, reimbursement and utilization.
QSP can inform designing First-in-Human clinical trials to help determine the starting dose and subsequent dose escalations to ensure human subject safety.
New executives’ scientific, operational and consulting expertise will support Simcyp’s footprint in drug development and regulatory decision-making.
In this webinar, Leticia Arrington (Merck) and Richard Franzese (Certara) discussed data considerations, analysis methods, and learnings from a recent network MBMA analysis of relevant endpoints in NP that will be used for general competitive landscaping questions to support Merck’s ongoing mission to develop better NP therapies.
PRINCETON, NJ – Mar. 13, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that its pharmacokinetic/pharmacodynamic (PK/PD), quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetic (PBPK) modeling experts will participate in 21 sessions at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2019 […]
The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Biologically-based therapeutic drugs comprise monoclonal antibodies (MAbs), vaccines, recombinant hormones and proteins, antibody-drug conjugates, RNAi, antisense, blood factors, and other large molecules. Although the success of biologics has been demonstrated, there are inherent operational and […]
Watch this webinar to learn why many major pharma organizations are investing in QSP for its potential to improve pharma R&D productivity.